ADENOSINE AND ANTIOXIDANT ENZYMES
腺苷和抗氧化酶
基本信息
- 批准号:2901240
- 负责人:
- 金额:$ 10.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-04-01 至 2001-03-31
- 项目状态:已结题
- 来源:
- 关键词:adenosine antioxidants catalase chemoprevention cytoprotection electron microscopy enzyme activity enzyme substrate free radical oxygen glutathione peroxidase hydrogen peroxide ischemia lactate dehydrogenases northern blottings organelles oxidative stress phosphorylation protein kinase C respiratory hypoxia site directed mutagenesis superoxide dismutase tissue /cell culture western blottings
项目摘要
Oxygen free radicals, such as singlet oxygen, superoxide anion and
hydroxyl radicals, are normal byproducts of oxygen utilization by the
tissue. Reducing the cellular load of these radicals is a major goal in
medicine since free radicals have been implicated in Alzheimer's disease,
Parkinson's disease, cancers, ischemia-reperfusion injuries, inflammation
and also in the aging process. An antioxidant defense system provides
protection of the cell from free radicals and comprises enzymes such as
superoxide dismutase (SOD), catalase CAT), glutathione peroxidase (GSH.Px)
and glutathione reductase (GR) and nonenzymatic antioxidants such as
vitamins A, C and E and reduced glutathione. The nucleoside adenosine, a
metabolite of ATP, provides protection to tissues during myocardial and
cerebral ischemia. While the mechanism of cytoprotection is not clear, we
have recently demonstrated that adenosine and an analog R-phenylisopropyl
adenosine (R-PIA) promote rapid activation (observed within 30 min) of
antioxidant enzymes by 2-3 fold by activating an AAR subtype coupled to
phospholipase C in a rat basophilic clone (RBL-2H3 cells). A23187 (a Ca2+
ionophore) and phorbol esters (activators of protein kinase C) both
mimicked activation of these enzymes via the A3AR. Inhibition of protein
kinase C by staurosporine attenuated activation of these enzymes elicited
by both R-PIA and phorbol esters. Furthermore, the activities of purified
preparations of antioxidant enzymes could be regulated by protein kinase
C-mediated phosphorylation. These data suggest that stimulation of the
A3AR leads to activation of antioxidant enzymes, and that this activation
process likely involves phosphorylation by protein kinase C.
The major aims of this study are:
l. To determine the mechanism(s) by which this rapid activation of the
A3AR on the cell surface leads to activation of antioxidant enzymes. This
study will focus mainly on protein kinase C and would specifically
determine whether antioxidant enzymes are substrates of protein kinase C
in vitro and whether the A3AR promotes in vivo phosphorylation of these
enzymes. In addition, site-directed mutagenesis of potential
phosphorylation sites will be performed to determine the potential site(s)
of phosphorylation by protein kinase C. These latter studies will involve
mutagenesis of epitope tagged cDNAs of the different antioxidant enzymes.
2. To determine whether activation of antioxidant enzymes via the A3AR
provides protection to cells during hypoxia or undergoing oxidative
stress. Oxidative stress to RBL-2H3 cells, bovine aortic endothelial cells
and cardiac myocytes will be induced by hypoxia the addition of hydrogen
peroxide to the culture medium or by the addition of a mixture of
xanthine/xanthine oxidase for periods ranging from 1-2 h. A3AR-mediated
protection will be assessed by determining the levels of reduced and
oxidized glutathione, malondialdehyde and by electron microscopic studies
of cellular organelles.
3. To determine the long term effect of A3AR activation on antioxidant
enzymes. Cells (RBL-2H3 and human endothelial cells) will be treated with
R-PIA for periods ranging from 12-48 h and the "steady state" activities
and levels of various antioxidant enzymes will be determined
spectrophometrically and by Western blotting, respectively. Northern
blotting studies will determine whether the A3AR can regulate the RNA
encoding these enzymes.
Taken together, these studies will explore a novel mechanism of
cytoprotection provided by adenosine and might contribute to the
development of new treatments for myocardial and cerebral ischemia.
氧气自由基,例如单线氧,超氧化阴离子和
羟基自由基是正常的氧气副产品
组织。减少这些自由基的细胞负荷是一个主要目标
由于自由基已与阿尔茨海默氏病有关
帕金森氏病,癌症,缺血 - 再灌注损伤,炎症
以及在衰老过程中。抗氧化剂防御系统提供
保护细胞免受自由基的保护,包括酶,例如
超氧化物歧化酶(SOD),过氧化氢酶CAT),谷胱甘肽过氧化物酶(GSH.PX)
和谷胱甘肽还原酶(GR)和非酶抗氧化剂,例如
维生素A,C和E并减少谷胱甘肽。核苷腺苷,A
ATP的代谢产物,为心肌和
脑缺血。虽然细胞保护的机制尚不清楚,但我们
最近证明了腺苷和类似物R-苯基丙二醇胺
腺苷(R-PIA)促进快速激活(在30分钟内观察)
抗氧化剂酶通过激活AAR亚型耦合到2-3倍
大鼠嗜碱性克隆(RBL-2H3细胞)中的磷脂酶C。 A23187(Ca2+
离子载体)和佛波酯(蛋白激酶的活化剂C)均为
通过A3AR模仿这些酶的激活。抑制蛋白质
通过星形孢菌素减弱了这些酶的激活,激活了这些酶的激活
由R-PIA和Phorbol酯都通过。此外,纯化的活动
抗氧化剂的制剂可以由蛋白激酶调节
C介导的磷酸化。这些数据表明刺激
A3AR导致抗氧化酶的激活,并且这种激活
过程可能涉及蛋白激酶C的磷酸化。
这项研究的主要目的是:
l。确定这种快速激活的机制
细胞表面上的A3AR导致抗氧化酶的激活。这
研究将主要集中在蛋白激酶C上,并专门
确定抗氧化剂是否是蛋白激酶C的底物
体外以及A3AR是否促进这些体内磷酸化
酶。另外,电位定向诱变
将进行磷酸化位点以确定潜在位点
蛋白激酶C的磷酸化。这些后一种研究将涉及
表位的诱变标记了不同抗氧化剂酶的cDNA。
2。确定是否通过A3AR激活抗氧化酶
在缺氧期间为细胞提供保护或经历氧化的保护
压力。对RBL-2H3细胞,牛主动脉内皮细胞的氧化应激
缺氧将诱导心肌细胞和心肌细胞的添加
过氧化培养基或通过添加混合物
黄嘌呤/黄嘌呤氧化酶的周期范围为1-2小时。 A3AR介导的
通过确定降低的水平和
氧化的谷胱甘肽,丙二醛和电子显微镜研究
细胞细胞器。
3。确定A3AR激活对抗氧化剂的长期影响
酶。细胞(RBL-2H3和人内皮细胞)将用
R-PIA的期间为12-48 h,“稳态”活动
将确定各种抗氧化剂的水平
分光图和通过蛋白质印迹。北方
印迹研究将确定A3AR是否可以调节RNA
编码这些酶。
综上所述,这些研究将探索一种新的机制
腺苷提供的细胞保护作用,可能有助于
开发心肌和脑缺血的新疗法。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Adenosine A(2A) receptor mRNA regulation by nerve growth factor is TrkA-, Src-, and Ras-dependent via extracellular regulated kinase and stress-activated protein kinase/c-Jun NH(2)-terminal kinase.
神经生长因子对腺苷 A(2A) 受体 mRNA 的调节是 TrkA、Src 和 Ras 依赖性的,通过细胞外调节激酶和应激激活蛋白激酶/c-Jun NH(2) 末端激酶。
- DOI:10.1074/jbc.274.50.35499
- 发表时间:1999
- 期刊:
- 影响因子:0
- 作者:Malek,RL;Nie,Z;Ramkumar,V;Lee,NH
- 通讯作者:Lee,NH
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Vickram Ramkumar其他文献
Vickram Ramkumar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Vickram Ramkumar', 18)}}的其他基金
Oral Epigallocatechin Gallate (EGCG) for Treatment of Cisplatin Ototoxicity
口服表没食子儿茶素没食子酸酯(EGCG)治疗顺铂耳毒性
- 批准号:
10163157 - 财政年份:2018
- 资助金额:
$ 10.26万 - 项目类别:
Oral Epigallocatechin Gallate (EGCG) for Treatment of Alzheimer's Disease Induced Hearing Loss
口服表没食子儿茶素没食子酸酯 (EGCG) 用于治疗阿尔茨海默病引起的听力损失
- 批准号:
10288729 - 财政年份:2018
- 资助金额:
$ 10.26万 - 项目类别:
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
转铂:一种减轻顺铂毒性的新型药物
- 批准号:
8579608 - 财政年份:2013
- 资助金额:
$ 10.26万 - 项目类别:
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
转铂:一种减轻顺铂毒性的新型药物
- 批准号:
8688964 - 财政年份:2013
- 资助金额:
$ 10.26万 - 项目类别:
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
转铂:一种减轻顺铂毒性的新型药物
- 批准号:
9288153 - 财政年份:2013
- 资助金额:
$ 10.26万 - 项目类别:
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
转铂:一种减轻顺铂毒性的新型药物
- 批准号:
9096039 - 财政年份:2013
- 资助金额:
$ 10.26万 - 项目类别:
Targeting Inflammation for the Amelioration of Cisplatin-Hearing Loss
针对炎症改善顺铂听力损失
- 批准号:
8180477 - 财政年份:2011
- 资助金额:
$ 10.26万 - 项目类别:
Role of adenosine A3 receptor in suppressing prostate cancer
腺苷A3受体在抑制前列腺癌中的作用
- 批准号:
7516278 - 财政年份:2008
- 资助金额:
$ 10.26万 - 项目类别:
Nerve Growth Factor and Transient Receptor Potential (TRPV1) Channel in Diabetic
糖尿病患者的神经生长因子和瞬时受体电位 (TRPV1) 通道
- 批准号:
7457520 - 财政年份:2008
- 资助金额:
$ 10.26万 - 项目类别:
相似国自然基金
抗氧化剂/活性离子时序释放复合支架构建及其修复糖尿病骨缺损的机制研究
- 批准号:32360232
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
塑料抗氧化剂内分泌干扰转化产物的识别与环境行为研究
- 批准号:22306042
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
农用地膜抗氧化剂的土壤污染特征及其微生物效应与机制研究
- 批准号:42377223
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
自然水体轮胎抗氧化剂高毒醌类衍生物非靶向识别及生物转化机制
- 批准号:42377360
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
取代对苯二胺抗氧化剂及其醌衍生物的人体内暴露标志物研究
- 批准号:22306031
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Age-Related Obesity and Healthspan: Identifying Interventions and Mechanisms
与年龄相关的肥胖和健康寿命:确定干预措施和机制
- 批准号:
9171143 - 财政年份:2016
- 资助金额:
$ 10.26万 - 项目类别:
Hybrid Katp Channel Opener and Redox Catalyst for Lung Transplantation
用于肺移植的混合 Katp 通道开放剂和氧化还原催化剂
- 批准号:
8451621 - 财政年份:2013
- 资助金额:
$ 10.26万 - 项目类别:
A Bifunctional Katp Channel Activator and Redox Mimetic for BPD
BPD 的双功能 Katp 通道激活剂和氧化还原模拟物
- 批准号:
8449796 - 财政年份:2013
- 资助金额:
$ 10.26万 - 项目类别:
Radiocontrast Nephropathy: Redox Degradation Catalyst and Nitric Oxide Donor
放射性对比肾病:氧化还原降解催化剂和一氧化氮供体
- 批准号:
8449038 - 财政年份:2013
- 资助金额:
$ 10.26万 - 项目类别:
Prevention of Retinopathy of Prematurity with a Novel Bifunctional Redox Reagent
用新型双功能氧化还原试剂预防早产儿视网膜病变
- 批准号:
8051014 - 财政年份:2011
- 资助金额:
$ 10.26万 - 项目类别: